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Abstract 
To elaborate the decisive role of surfactants in promotion of aceclofenac’ skin absorption, 
potentially avoiding irritation, we developed non-ionic microemulsions varying natural or 
synthetic surfactants: sucrose esters (laurate or myristate) vs. polysorbate 80. A 
comprehensive physicochemical characterization indicated no significant influence of the 
solubilized nonsteroidal anti-inflammatory drug on the bicontinuous structure of blank 
formulations. To evaluate skin tolerability of isopropyl alcohol, a sucrose ester–based 
microemulsion containing transcutol P as a cosurfactant was also developed. The measured 
skin parameters strongly depended on the (co)surfactant type, showing higher compatibility of 
the microemulsions containing sucrose ester and isopropyl alcohol. In vitro release results, in 
vivo tape stripping and pharmacokinetics in rats confirmed superiority of the sucrose ester– 
over polysorbate–based microemulsions (total amounts of aceclofenac penetrated 60.81 ± 
5.97 and 60.86 ± 3.67 vs. 27.00 ± 5.09 µg/cm2, and its maximum plasma concentrations 
275.57 ± 109.49 and 281.31 ± 76.76 vs. 150.23 ± 69.74 ng/ml for sucrose laurate– and 
myristate– vs. polysorbate 80–based microemulsions, respectively). Hence, sugar–based 
excipients increased delivery of aceclofenac through stratum corneum by increasing its 
fluidity, showing overall more satisfying safety profiles. In conclusion, sucrose ester–based 
microemulsions proved to be promising carriers for dermal/transdermal aceclofenac delivery. 
 
Keywords: Bicontinuous microemulsion; Sucrose ester; Aceclofenac; Skin irritation 
potential; Tape stripping; Pharmacokinetics 
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1. Introduction 
Aceclofenac (AC) is an orally effective nonsteroidal anti-inflammatory drug (NSAID), 
indicated for use in patients with osteoarthritis, rheumatoid arthritis and ankylosing 
spondylitis, as well as for the symptomatic therapy of pain and inflammation (Jana et al., 
2013). Although efficacious and relatively safe, chronic oral AC administration may cause 
systemic side effects characteristic for NSAIDs, due to inhibition of prostaglandin synthesis 
(Raza et al., 2014), which warrants the search for a new route of its administration in the 
therapy of musculoskeletal disorders. AC has both hydrophobic and hydrophilic properties 
and log P value close to 2, within an optimal range for candidates for dermal/transdermal 
delivery following topical application (Beetge et al., 2000; Dave et al., 2015; Heyneman et al., 
2000). An ease of application, reduced drug degradation, decreased side effects, avoiding 
first-pass metabolism and enhanced patient compliance would all be potential benefits of 
topical over oral AC administration, if the condition of comparable efficacy is fulfilled (Jana 
et al., 2014; Raza et al., 2014). 
The crucial step during any topical NSAID therapy is the drug’s ability to overcome the 
outermost layer of the skin – stratum corneum (SC), as the critical barrier for penetration of 
an active through the skin in sufficiently high amount to exert its clinical effect (Brunner et 
al., 2011; Changez et al., 2006; Jana et al., 2014; Raza et al., 2014). Consequently, in our 
research, colloidal carrier systems – microemulsions are introduced as promising vehicles for 
dermal/transdermal delivery of AC (Al Abood et al., 2013; Naoui et al., 2011; Sahle et al., 
2013; Schwarz et al., 2012). They represent a transparent, optically isotropic, 
thermodynamically stable amphiphile-stabilized dispersion of otherwise two immiscible 
phases – water and oil (Bardhan et al., 2013). The increased interest in microemulsions stems 
from their potential benefits over traditional formulations, such as immense interfacial area 
with corresponding high solubilization capacity, penetration enhancement through the 
 5 
 
biological membranes, high stability and ease of preparation (Das and Mitra, 2014; Sahle et 
al., 2012). Depending on the composition, spontaneous curvature and flexibility of the 
surfactant film, they can be characterized as water in oil, oil in water or bicontinuous 
(domains of water and oil co-exist together) systems (Das and Mitra, 2014; Formariz et al., 
2008). While the curvature of the surfactant film tends to zero, the interface becomes fluid 
enough and droplets coalesce during collisions, resulting into equilibrium bicontinuous 
structure made of interconnected three-dimensional networks of water and oil (Naoui et al., 
2011). Such dynamic structures are characterized by a higher amphiphilic character, greater 
fluctuating interface, a lower interfacial tension and improved solubilizing properties when 
compared to both globular types of microemulsions (Bhatia et al., 2013; Naoui et al., 2011). 
Considering the high concentration of surfactant and/or cosurfactant, the main challenge in 
topical microemulsion formulation is to effectively increase the penetration of a drug through 
the SC while avoiding skin irritation (Yuan et al., 2008). Consequently, the choice of 
components is challenging and, beside their ability to form stable microemulsions, should 
carefully take into account their biological and pharmaceutical acceptability (Changez et al., 
2006; Das and Mitra, 2014). Here, there is a growing interest in using non-ionic surfactants, 
which are reportedly less toxic and irritant than other types of surfactants, and are commonly 
classified on the ethylene oxide-based (e.g. polysorbates – P) and polyhydroxy-based (e.g. 
sucrose esters – SEs) surfactants (Kovacevic et al., 2011; Tadros, 2005). SEs are meant to be 
nontoxic surfactants obtained from a naturally occurring carbohydrate, with features of low 
skin sensitization and enhancing skin penetration, as well as with a high environmental 
compatibility, all of which may be distinct advantages when compared to P, the 
conventionally used synthetic ethoxylated surfactants (Ayala-Bravo et al., 2003; Schwarz et 
al., 2012; Szűts and Szabó-Révész, 2012; Tadros et al., 2005). 
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A detailed introductory analysis of the phase behavior and structural aspects of 
microemulsion systems, comprising SE, isopropyl alcohol (IPA), isopropyl myristate (IPM) 
and ultra-purified water, has been recently presented by our group (Todosijević et al., 2014). 
To extend that study, we used the previously selected biocompatible microemulsions, in order 
to compare their physicochemical and biopharmaceutical properties, as well as their skin 
tolerability and ability for dermal/transdermal AC delivery, assessed via in vivo penetration 
study in human volunteers and in vivo pharmacokinetic study in rats, with non-ionic 
microemulsion based on the synthetic surfactant – P. We hypothesized that structural 
differences in the used surfactants may result in distinctive changes in nanostructure, skin 
tolerability and penetration-enhancement capability of non-ionic microemulsions. An attempt 
has also been made to investigate the influence of the chain length of SEs on the measured 
parameters. 
2. Materials and methods 
2.1. Materials 
AC was purchased from Jinan Jiaquan Chemical Co. Ltd (China). Sucrose laurate D-1216 
(SL) and sucrose myristate C-1416 (SM), used as surfactants, were generously donated by 
Mitsubishi-Kagaku Foods Corporation (Tokyo, Japan). SEs were chosen in such a way that 
the purity of the main fatty acid (lauric and myristic acid in the case of SL and SM, 
respectively) equals 95%, they have the same HLB value of 16, ester composition (80% 
monoester and 20% di-, tri- and polyester) as well as head group, while differ in the tail 
length. Polysorbate 80 (P80), also used as a surfactant, was obtained from Sigma–Aldrich 
Laborchemikalien GmbH (Seelze, Germany). IPA (Brenntag, Wien, Austria) and IPM 
(Comcen, Belgrade, Serbia) were used as a cosurfactant and an oil phase, respectively. Ultra-
purified water (GenPure apparatus, TKA Wasseranfbereitungssysteme GmbH, Neiderelbert, 
Germany) was used as a hydrophilic phase. 
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2.2. Preparation of AC-unloaded and AC-loaded microemulsions 
The pseudo-ternary phase behavior of the system IPM/SE-IPA/ultra-purified water, at fixed 
surfactant-to-cosurfactant weight ratio 1:1 (Km), has been described in our previous work with 
the help of phase diagrams (Todosijević et al., 2014). The current investigation extends our 
previous study with the comprehensive characterization of the selected SE-based 
microemulsions, which showed maximum solubilization capacity for AC. For the purpose of 
the comparison, P80-based microemulsion was also developed, with the same ratio of 
components (Km ratio 1:1, and (surfactant + cosurfactant)-to-oil weight ratio 9:1). Briefly, 
microemulsions were prepared at the room temperature as described: appropriate mass of 
ultra-purified water (35% w/w) was added into mixture of oil and surfactant blend (Km ratio 
1:1) under magnetic stirring. AC was incorporated into prepared microemulsions to give the 
final concentration of 2% (w/w). The given names and composition with the weight ratio of 
each component of the studied blank formulations are given in Table 1. 
2.3.Microemulsion characterization 
2.3.1. Polarization microscopy 
Microemulsions, as isotropic and transparent systems, do not interfere with the polarized 
light. Thus, blank and AC-loaded microemulsions were checked for the lack of birefringence 
(and for the presence of drug crystals) using Motic digital microscope DMB3-223ASC and 
Motic Images Plus v.2.0 software (Motic GmbH, Wetzlar, Germany). 
2.3.2. pH measurements 
The pH value of the blank and AC-loaded microemulsions was measured using HI9321 pH 
meter (Hanna Instruments Inc., Ann Arbor, Michigan). The measurements were performed in 
triplicate at 25°C. 
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2.3.3. Electrical conductivity measurements 
The electrical conductivity of the samples was measured using CDM230 Conductivity Meter 
(Radiometer, Copenhagen, Denmark). The measurements were performed in triplicate at 
25°C. 
2.3.4. Rheological measurements 
The rheological behavior of the samples was evaluated using DV-III ULTRA Programmable 
Rheometer and Rheocalc software v.4.3 (Brookfield Engineering Laboratories, Middlesboro 
USA), equipped with cone and plate measuring device. The shear stress measurements were 
performed within the shear rate range from 375 to 1875 s−1, and back to the start point, at 20 ± 
1°C. 
2.3.5. Differential Scanning Calorimetry (DSC) 
DSC investigation was performed using Mettler Toledo DSC 1, STARe System (Mettler 
Toledo GmbH Analytical, Giessen, Germany), and thermoanalytical parameters (i.e. enthalpy, 
onset, and peak temperature) associated with each thermal transition, were obtained by 
integration of the area of the relevant DSC peaks, using Mettler Toledo STARe Software. To 
evaluate the physical state of AC in microemulsions, the samples were precisely weighted (5 
to 10 mg) into 40-µl aluminum pan, hermetically closed, and scanned between 25 to 200°C, at 
a heating rate of 10°C/min. Additionally, to investigate the microemulsion structure by 
evaluation of the water behavior, approximately the same amount of the sample was 
accurately weighted, aluminum pans were hermetically sealed, and DSC curves were 
generated by cooling the samples from 25 to -60°C, with a cooling rate of 5°C/min. In both 
investigations, nitrogen with a flow rate of 50 ml/min was used as a purge gas, and an empty 
sealed aluminum pan was used as a reference. 
2.3.6. Thermogravimetric Analysis (TGA) 
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TGA was introduced in order to better assess the mode of water distribution in the developed 
microemulsions. Small amount of the sample was placed in an open aluminum pan and heated 
in Netzsch STA 409PG (Netzsch, Selb, Germany), at a heating rate of 5°C/min, from 25 to 
130°C under constant helium flow (40 ml/min). 
2.3.7. Fourier Transform Infrared Spectroscopy (FTIR) 
For precise evaluation of the chemical interaction among AC and other ingredients, spectral 
scanning was performed in the wavelength range between 4000 and 400 cm-1, with a 
BOMEM Hartmann & Braun MB-Series FTIR spectrophotometer (ABB Bomem Inc., 
Quebec, Canada). The FTIR spectrum of the pure AC was obtained using the potassium 
bromide pastille method. For microemulsion samples (blank and AC-loaded microemulsions) 
and for liquid excipients (ultra-purified water, IPM, IPA and surfactant blend), a 10 µL of the 
sample was placed on the KRS-5 plate. The FTIR spectra of all samples were recorded with a 
resolution of 4 cm-1, using 10 scans for each spectrum. 
2.3.8. Atomic Force Microscopy (AFM) 
Morphology of blank and AC-loaded microemulsions was observed using AFM. 48 h prior to 
the investigation, 10 μL of the sample was directly deposited onto a small, circular mica disc 
(Highest Grade V1 AFM Mica Discs; Ted Pella Inc., Redding, California) and dried in 
desiccator. Measurements were performed with NTEGRA prima AFM (NT-MDT, Moscow, 
Russia) operating in intermittent-contact AFM mode in air. For this purpose, NT-MDT 
NSGO1 silicon cantilevers (N-type, Antimony doped, Au reflective coating) were used. 
Nominal force constant of these cantilevers is 5.1 N/m, while their resonance frequency lies in 
the range 87-230 kHz. During the measurements cantilever driving frequency was 156 kHz, 
and line scanning frequency was 1 Hz. Both topography and “error signal” AFM images were 
taken and later analyzed using the software Image Analysis 2.2.0 (NT-MDT, Moscow, 
Russia). 
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2.4. In vivo assessment of blank samples’ irritation potential 
Ten healthy female volunteers (aged 21 – 23), without reported skin diseases or skin lesions, 
and with no history of allergic reactions, participated in the 24-h study under occlusion after 
signing the inform consent. Prior to the experiment, the volunteers were informed about the 
protocol, agreed to participate in the study, and they were asked not to apply any topical 
products on the forearm up to 24 h prior to the experiment. Signed written consents were 
obtained in accordance with the Helsinki Declaration and local Ethical Committee. 
Taking into account that IPA may cause dry skin, the irritation potential of developed 
microemulsions (FL, FM and FP) was compared with those which are quantitatively the same, 
but differ in the type of cosurfactant (named FT, Table 1), as explained in Supplementary 
material. In vivo safety potential of the blank samples FL, FM, FP and FT was assessed via 
three skin parameters – transepidermal water loss (TEWL), erythema index (EI), and SC 
hydration (SCH). On the day of experiments, volunteers were instructed to spend 30 min in 
the study room prior to measurements in order to adapt to room conditions (temperature 23 ± 
1°C, relative humidity 35 ± 5%). Afterwards, on the previously delimited test areas, SCH, 
TEWL, and EI of forearm skin surface were measured using Cutometer® MPA 580, 
Mexameter® MX18 and Tewameter® TM210, respectively, from Courage Khazaka (Köln, 
Germany). Two sites were left untreated as controls: non-treated control under occlusion 
(NCO) and without occlusion (NCWO). After initial measurements, blank microemulsions 
were applied and covered with 8 mm Finn Chambers® (Smart Practice, Phoenix, Arizona, 
USA). After 24-h occlusion, the chambers were removed, and 60 min later, all parameters 
were reassessed on the same position on the flexor aspects of forearms. Parameters are 
presented as percentage change of the second versus the first day as the baseline. 
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2.5. In vitro release studies through synthetic membrane 
In vitro release profiles were assessed through the previously rehydrated artificial membranes 
(0.2 µm cellulose membrane, Sartorius, Stedim Biotech GmbH, Göttingen, Germany) 
mounted on Franz cells with the available diffusion area of 0.785 cm2. Precise volume (8-9 
ml) of the freshly prepared phosphate buffer (pH 7.4) was placed in the receiver compartment 
and magnetically stirred at 300 rpm. The accurately weighted AC-loaded formulation (400-
420 mg) was placed on the cellulose membrane in the donor chamber, taking care to avoid 
incorporation of air bubbles which limit the diffusion of drug. Franz cells were mounted in a 
water bath at 37°C, while the temperature of the membranes was 32°C. Aliquots of 500 µl of 
the acceptor medium were collected from the receiver cell at regular time intervals over 6 h 
(the sampling was performed at 0.5, 1, 1.5, 2, 3, 4, 5 and 6 h) and filtrated using 0.45 µm MF-
Millipore® membrane filter (Millipore Corporation, Bedford, USA). In order to maintain sink 
conditions, each aliquot was replaced with the same volume of the fresh preheated medium. 
AC concentration was determined using high performance liquid chromatography (HPLC, 
Dionex, UltiMate 3000 Thermo Scientific, Germering, Germany): 20 µl of the sample was 
injected through a partial loop, separations were performed on a Luna C18 column (100 A, 
250 mm x 4.6 mm, 5 µm), whereas the mobile phase consisted of acetonitrile/methanol/0.5% 
w/v ammonium acetate (pH = 5.9) (27/18/55). The flow rate of the mobile phases was 1 
ml/min, and the column temperature was set at 25°C. UV detection was performed at 274 nm. 
The experiments were carried out in triplicate, and results were plotted as the cumulative 
released drug percentage versus time. Statistical and model-dependent methods were 
proposed to compare the obtained drug release profiles. The obtained AC liberation profiles 
were assessed by fitting experimental data to the mathematical equations describing the 
following kinetic models: Higuchi, zero order, first order and Korsmeyer-Peppas 
mathematical models (data available in Supplementary Material). Linear regression analysis 
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was performed, and the model which gave the highest correlation coefficient (R2) value was 
considered to be the most suitable kinetic model for describing the release of AC from the 
investigated systems. 
2.6. In vivo skin absorption assessment – tape stripping method 
Three healthy females (aged 23 – 26), who had no history of skin diseases or allergic 
reactions, participated in the study after signing the inform consent. On the day of 
experiments, volunteers were instructed to spend 30 min in the study room prior to 
measurements in order to adapt to room conditions. All samples were uniformly applied 
topically, on the intact skin areas previously delineated using a permanent marker pen to 
ensure that the SC layers were removed throughout the experiment on the same position. 
After a residence time of 1 h, which is the application time selected based on the similar 
works (Mahrhauser et al., 2014; Schwarz et al., 2013; Teichmann et al., 2007), SC layers were 
removed using twelve adhesive D-squam® tapes with surface area of 3.8 cm2. After applying 
the uniform pressure of 140 g/cm2 for 10 s, each tape was stripped rapidly in a single 
movement. TEWL proved as a useful parameter in the assessment of the functional state of 
the skin barrier, and therefore it was measured at the baseline, after 7th and the last (12th) 
tape. Additionally, measurement of TEWL allows normalization of the individual skin 
thickness, permitting the expression of drug concentration profile (µg/cm2) as a function of 
relative position within the SC (x/L) (Hathout et al., 2011; Jaksic et al., 2012). The apparent 
thickness of SC (L) was calculated as described elsewhere (Kalia et al., 2001), whereas 
estimation of the removed SC layer thickness (x), was done by determination of the precise 
weight of each tape after removal using the equation explained in the work of Jakšić et al. 
(2012). 
The amount of AC was determined in the supernatant, obtained after sonification (Sonorex 
RK102H, Bandelin, Berlin, Germany) of each tape (first two tapes were discarded) with 5 ml 
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of ethanol (70% v/v) for 15 min, followed with centrifugation (Centrifuge MPW-56, MPW 
Med. Instruments, Warszawa, Poland) at 4000 rpm for 5 min. Afterwards, samples were 
filtered through 0.45 µm MF-Millipore® membrane filter and assayed by liquid 
chromatography–tandem mass spectrometry (LC–MS/MS). 
2.7. In vivo pharmacokinetic study in rats 
Experiments with animals were conducted in compliance with the EEC Directive 86/609. The 
protocol was reviewed and approved by the Ethical Committee on Animal Experimentation of 
the Faculty of Pharmacy, University of Belgrade, Serbia. Male Wistar rats (Military Farm, 
Belgrade, Serbia) were housed in plastic cages, on a 12-h light-dark cycle, with free access to 
pellet food and tap water. The temperature of the animal room was 22 ± 1°C, the relative 
humidity 40–70%, and the illumination 120 lx. 
Briefly, the rats were divided into 5 groups and treated as follows: 
Group 1: topical application of 200 µl of AC-loaded SL-based microemulsion (FLAc); 
Group 2: topical application of 200 µl of AC-loaded SM-based microemulsion (FMAc); 
Group 3: topical application of 200 µl of AC-loaded P80-based microemulsion (FPAc); 
Group 4: intravenous application of AC solution (25% of ethanol (96% v/v) and 75% of the 
phosphate buffer, pH = 7.4); 
Group 5: subcutaneous application of the AC solution. 
In the groups intended for topical application (groups 1-3), one day prior the experiment, 
animals were lightly anesthetized by i.p. injection of ketamine (10% Ketamidor, Richter 
Pharma Ag, Wels, Austria), and hair of the back was shaved and afterwards washed gently 
with distilled water. On the day of experiment, samples were applied to the shaved region via 
open containers glued to the skin, delimited to the surface area of 2.01 cm2. In order to 
prevent formulation leakage, the containers were tightly covered with the silicone film 
(Parafilm®, USA). In the group 4 intended for i.v. administration (15 mg/kg), AC solution was 
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infused into the tail vein using a syringe pump (Stoelting Co., Wood Dale, USA), whereas the 
same dose of the AC solution was injected subcutaneously in the last group of rats. 
In all groups, blood samples (200 µL) were collected from the tail vain, at the predetermined 
time intervals (20 min, 40 min, 60 min, 3 h, 6 h, and 24 h of post-dose) in heparinized tubes. 
The plasma (100 µL) was separated immediately by centrifugation at 3000 rpm for 15 
minutes (Eppendorf MiniSpin® plus centrifuge, Westbury, NY, USA). AC was extracted 
using the modified procedure by Mutalik et al. (2008), in which 100 µl of rat plasma, 25 µl of 
methanol and 200 µl of acetonitrile were added to tube, vortexed for 60 s and 675 µl of 
diluent (methanol and ultra-purified water in the mixture of 80:20 (v/v)) was added up to 1 ml. 
The resulting solution was vortexed for 60 s and centrifuged at 10000 rpm for 10 min. 
Preparation of calibration standards in plasma was done by addition of 5 µl of the working 
standard solutions (containing 1, 2, 5, 10, 20, 30, 50 and 70 µg/ml of aceclofenac and the 
same concentration of diclofenac using methanol) into 95 µl of plasma, followed by the same 
procedure as described above. Subsequently, the supernatant was separated and analyzed 
using LC–MS/MS system. 
Using Microsoft® Excelbased program PK Functions (Usansky, Desai and Tang-Liu, 
Department of Pharmacokinetics and Drug Metabolism, Allergan, Irvine, California), the 
following pharmacokinetic parameters were calculated: the maximum plasma concentration 
of AC and diclofenac (cmax and c*max, respectively), the time to reach the maximum plasma 
concentration of AC and diclofenac (tmax and t*max, respectively), and the area under the 
plasma concentration curve as a function of time, from time zero to the time of the last 
measured concentration (c24), of AC and diclofenac (AUC0–24 and AUC*0–24, respectively). 
2.8. LC–MS/MS 
LC-MS/MS was used for detection of AC in each stripped sample as well as for detection of 
AC and diclofenac in rat plasma. Each sample was injected into a Thermo Scientific Accela 
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600 UPLC system connected to a Thermo Scientific TSQ Quantum Access MAX triple 
quadrupole mass spectrometer (Thermo Fisher Scientific, San Jose, California) equipped with 
heated electrospray ionization (HESI) source. XTerra® MS C18 column (2.1 × 150 mm2, 3.5 
µm; Waters Corporation) was used as a column, whereas mobile phase consisted of 
acetonitrile and 0.1% formic acid (75:25, v/v) at a flow rate of 0.5 mL/min. Total analysis 
time was 2.2 min at temperature 25°C. High-purity nitrogen was used as nebulizing gas in the 
HESI source. HESI source and MS parameters were as follows: spray voltage 5 kV, vaporizer 
temperature 400°C, sheath gas pressure 50 units, ion sweep gas 0 units, auxiliary gas 45 units, 
ion transfer capillary temperature 300°C, capillary offset 15 units, tube lens offset 96 units, 
skimmer offset 20 units, peak width relating to resolution 0.7 for Q1, scan with (m/z) 0.02, 
scan time 200 ms. Quantification was conducted using selected reactions monitoring in 
positive scan mode for AC and diclofenac: 353.8→213.9 m/z and 296.0→214.0 m/z, 
respectively. 
2.9. Statistical analysis 
Statistical analysis was performed using IBM SPSS® Statistics 19 software (IBM, NY, USA). 
Statistical analysis of in vitro release data was carried out using one-way analysis of variance 
(ANOVA) followed by Tukey's post hoc test. The parameters from the in vivo skin irritation 
experiments (SCH, EI, TEWL), measured on the second day, were compared to the baseline 
values using Mann–Whitney U-test. For in vivo effects (SCH, EI, TEWL), percentage 
changes (second versus first day) of the placebo samples were compared mutually and related 
to the NCWO and NCO, using the one-way ANOVA, followed by either Tukey's or the 
GamesHowell post hoc test, when p value in Levene's test for homogeneity of variance was 
greater than 0.05 or below 0.05, respectively. Parameters of in vivo tape stripping (total 
amount of AC penetrated) and pharmacokinetic experiments (cmax and AUC0-24) were 
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assessed with the one-way ANOVA followed by Tukey's post hoc test. Statistical significance 
was set at p < 0.05. 
3. Results and discussion 
3.1. Physicochemical characterization – determination of microemulsion nanostructure 
Incorporation of AC into microemulsions has affected the pH value of each formulation in a 
similar degree, due to the acidic properties of the drug (Table 2). The pKa value of AC (pKa = 
4.7) (Cordero et al., 1997), in parallel with the present experimental results, indicated 
existence of a large fraction of the unionized drug. This is pertinent, as unionized moiety of a 
NSAID is expected to contribute to a better skin penetration, thus  increasing the 
bioavailability of the drug, whereas the ionized moiety limits dermal/transdermal permeation 
due to lower solubility in SC lipids (Beetge et al., 2000; Cordero et al., 1997). 
All tested microemulsions showed a linear relationship between shear stress and shear rate 
(data not shown), demonstrating Newtonian flow behavior with the apparent viscosity values 
in the range of 16-27 mPa s (Table 2). Very low viscosity, in parallel with the lack of 
birefringence under polarized light, distinguished these systems from liquid crystalline 
structures, which possess closely related type and proportion of components (Formariz et al., 
2008). While viscosity of a microemulsion vehicle depends on the composition, i.e. water and 
surfactant content (Ren et al., 2014), and our formulations were selected so that the 
concentration of components is the same, the viscosity of developed microemulsions 
apparently depended on the type and structure of surfactant, as shown in Table 2. Viscosity 
values tended to increase slightly in the case of P80-based microemulsions (FP and FPAc) in 
comparison to SE-based systems, and this trend followed the increment in the molecular 
weight of surfactants (524.6, 552.65, 1310 g/mol for SL, SM and P80, respectively). It should 
be noted that the presented SEs’ molecular weights represent the weights of sucrose 
monolaurate and sucrose monomyristate, which equal 80% of the total surfactant content. 
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Incorporation of AC slightly affected the viscosity of the microemulsions, but did not change 
the general flow behavior. 
Conductivity values, presented in Table 2, indicated the presence of conductive paths, which 
are responsible for the conductance of the system (Ustündağ Okur et al., 2014). These values, 
together with the full study of conductivity behavior along selected water dilution line 
((surfactant + cosurfactant)-to-oil weight ratio 9:1), as examined in our former study 
(Todosijević et al., 2014), suggested bicontinuous structure of the investigated samples. In the 
microemulsions containing AC, the electrical conductivity increased only slightly in 
comparison to unloaded formulations, confirming the absence of significant fraction of the 
ionized drug, which is in line with pKa value of AC and the measured pH values. 
The exothermic water peaks at very low temperatures on DSC cooling curves of the samples 
FL, FM, and FP (Fig. 1) indicated either a bicontinuous or water in oil microemulsion 
(Bardhan et al., 2013; Sahle et al., 2013). Notably, in the case of water in oil microemulsions, 
the interactions with the rest of the system profoundly altered thermodynamic properties of 
water, moving its freezing point to the extremely low temperatures, below the set limit of 
detection, as also shown in our previous study (Todosijević et al., 2014). These results 
suggested that hydration of surfactant, in combination with partial miscibility and hence 
interaction with IPA, is a likely reason for the absence of sharp exothermic peak of ultra-
purified water at −6.92°C. Moreover, the peak of bound water on DSC thermograms was 
slightly moved to the lower temperatures in the case of SL-based (-44.94 and -44.80°C, for 
FL and FLAc, respectively) in comparison to SM-based systems (-42.37 and -42.82°C for FM 
and FMAc, respectively). Because of the shorter chain length, and therefore more hydrophilic 
nature of SL, the binding capability of water was more distinct with respect to SL than to SM, 
resulting in the freezing peaks at the lower temperatures. Although the addition of a drug into 
the colloidal carrier system might have affected the nanostructure of the system, due to its 
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influence on the surfactant film and the interaction between surfactant and vehicle molecules 
(Junyaprasert et al., 2007; Liu and Chang, 2011), the DSC thermograms did not reveal any 
significant effect of the solubilized AC on the water behavior. 
DSC heating curves are presented in Fig. 2a. The DSC thermogram of pure AC showed an 
endothermic peak at 152.86°C, corresponding to the melting point of the drug. The broad 
endothermic peak in the range of approximately 50 to 115°C corresponded to the evaporation 
of the IPA (onset 78.58°C, peak 82.23°C) and ultra-purified water (onset 98.29°C, peak 
103.01°C), which was confirmed by the partial weight loss of the samples over the predefined 
temperature ranges, detected on the TGA thermograms (data not shown). FTIR spectra of 
pure AC, blank and AC-loaded microemulsions are shown in Fig. 2b. As presented in 
Supplementary material, the FTIR spectrum of AC contained peaks consistent with the 
literature data (Jana et al., 2014; Suresh et al., 2014). Moreover, the bands shown in FTIR 
spectra of blank microemulsions clearly appeared at the same wavenumbers in the spectra of 
AC-loaded microemulsions, without any new peaks or potential shifts, suggesting no 
alteration in the microemulsion structure upon drug incorporation (Hathout et al., 2010). 
These results, in parallel with DSC heating curves, proved that AC was completely 
solubilized in the investigated microemulsions, without any drug recrystallization or any 
chemical interactions among functional groups. 
Atomic force micrographs, shown in Fig. 3, represent the structures that can be found in 
bicontinuous microemulsions with intertwining oil and water phases. In 2D error signal 
images it can be clearly seen that distinct water droplets are still in contact with each other, 
further leading to the formation of water clusters and channels which coexist with oil 
domains. As shown in Fig. 3b, the addition of AC did not significantly influence the vehicles' 
nanostructure. Hence, physicochemical experimental techniques, together with atomic force 
micrographs, indicated that the bicontinuous structure of microemulsions is not prone to 
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further rearrangement induced by incorporation of the drug. Namely, the observed slight 
changes in some physicochemical parameters (pH and conductivity) were probably related to 
the intrinsic properties of AC as the model drug (Junyaprasert et al., 2007). 
3.2. Microemulsions – skin irritation potential 
The one-way ANOVA revealed a significant group effect on all investigated skin parameters: 
SCH (F(5, 54) = 29.543; p < 0.001), EI (F(5, 54) = 10.105; p < 0.001) and TEWL (F(5, 54) = 6.252; 
p < 0.001). One hour after occlusion removal, the significant difference for formulations FL 
and FM, which differ only in the surfactant chain length, could only be observed in the values 
of SCH (Fig. 4a), compared to baseline, NCO, and NCWO (p < 0.001 for all comparisons), 
without changes in EI and TEWL (Fig. 4b and 4c, respectively). Significant dehydration may 
be a consequence of high IPA concentration in these samples. However, in the case of P80-
based microemulsion, the observed decrease of SCH was far from reaching statistical 
significance (p = 0.364), which can be explained only as an influence of the distinct difference 
in the structure of surfactant, having in mind the same concentration of IPA in FL, FM and FP 
samples as well as the same bicontinuous structure of these formulations. Namely, hydroxyl 
groups of SEs are responsible for stronger hydrogen bonds with water molecules, whereas 
oxygen in polyethylene glycol binds water much weaker (Kovacevic et al., 2011), and these 
interactions may be responsible for higher skin dehydration after application of the vehicles 
which contain SEs as a surfactant. This finding is important as low hydration may result in an 
improved penetration of actives through SC. On the other hand, FP and FT were the samples 
showing some irritation potential (Supplementary material), due to the significant increase in 
EI after occlusion removal vs. baseline (p < 0.05 and p < 0.01, respectively), whereas the skin 
tolerability of the formulations FL and FM was acceptable. Additionally, for the former, but 
not the latter two formulations, TEWL was significantly increased in comparison to the basal 
values (p < 0.05 and p < 0.01, respectively), probably indicating alteration in the skin barrier 
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function. The increase in TEWL values detected after application of the ethoxylated surfactant 
is in line with the findings of Bárány et al. (2000), and with the fact that SEs, unlike 
polysorbates, do not remove the cutaneous fat film and are not expected to denature proteins 
of the skin surface (Bolzinger-Thevenin et al., 1998). Taking together this part of the study, 
the investigated SE-based samples with SL and SM showed overall satisfying safety profiles, 
supporting more acceptable skin tolerability of microemulsions based on natural surfactants, 
than those containing synthetic P80. 
3.3. In vitro release study 
Considering the total amount of released AC after 6 h, the one-way ANOVA demonstrated a 
significant group effect (F(2, 6) = 33.756; p = 0.001). As presented in Fig. 5, significantly 
higher total percentage of AC was released from SL- and SM-based systems (p < 0.001 and p 
= 0.014, respectively) in comparison to the microemulsion with P80 (87.28 ± 4.89 and 70.66 
± 4.46 vs. 53.65 ± 5.62%, respectively). Since all microemulsions have the bicontinuous 
structure, with the same total concentration of tensides and equal quantity of drug, 
concentration gradient is not the only factor governing drug release. In addition, the low pH 
value of all formulations excluded the potential influence of drug ionization on the liberation 
process. The higher amount of released AC may be a consequence of a slightly lower 
viscosity of drug-loaded FL and FM formulations (FLAc and FMAc; Table 2), and a release-
enhancing effect of SEs, evident in results showing that SEs increase the liberation of poorly 
water-soluble drugs (Szűts and Szabó-Révész, 2012). Additionally, a significant enhancement 
(p = 0.016) in AC release from sample FLAc, comparing to SM-based microemulsion, was 
observed (87.28 ± 4.89 vs. 70.66 ± 4.46%, respectively). This tendency correlates well with 
the higher AC solubility in SL/IPA than in SM/IPA mixture (Todosijević et al., 2014) and 
with lower viscosity of SL-based microemulsions (Table 2). It can be deduced from these 
results that the type of surfactant played an important role in the release of AC. The in vitro 
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liberation profiles were also evaluated kinetically, by fitting the experimental data into 
different order kinetic equations (Table S1), and these results are presented in Supplementary 
Material (Table S2). 
3.4. Tape stripping 
Fig. 6a shows the amount of penetrated AC from different formulations, determined on the 
removed tape strips as a function of the normalized SC depth. The one-way ANOVA revealed 
a significant group effect on the total amount of AC penetrated into SC (F(2, 6) = 15.240; p = 
0.004), as presented in Fig. 6b. By comparing the respective dermatopharmacokinetic profiles 
it can be observed that the amount of drug penetrated into SC was significantly higher in the 
case of SE-based microemulsions in comparison to FPAc (p < 0.01 for both comparisons). 
Due to the same AC concentration in microemulsions, and the absence of drug crystals 
observable by AFM or polarization microscopy, concentration gradient or thermodynamic 
activity of the drug cannot be considered as factors responsible for the differences in drug 
penetration. Therefore, SEs in the samples FLAc and FMAc may have contributed to the 
increased drug penetration into the SC. Indeed, it was proposed that SEs alter the ordered 
structure of the intercellular lipid region in the SC by insertion of the hydrocarbon chains 
between lipophilic tails of the bilayer, as well as by interaction of the sucrose ring with the 
polar head groups of the skin lipids (Ayala-Bravo et al., 2003; Cázares-Delgadillo et al., 2005; 
Yang et al., 2002). In line with the observed reduction in the hydration of skin (Fig. 4a), the 
proposed mechanism might have led to an increase in molecular motion of the SC, and thence 
an enhanced diffusion of the drug into skin. The results of tape stripping experiment, together 
with a higher quantity of AC released from SE-based microemulsions (Fig. 5), suggest 
superiority of both SEs over P as a surfactant in microemulsion formulations for 
dermal/transdermal AC delivery. With respect to the possible differences between two SEs, 
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our results did not reproduce the finding on a higher penetration efficacy of surfactant with 
lauryl hydrophobic chain (Ganem-Quintanar et al., 1998). 
3.5.Pharmacokinetic study in rats 
Fig. 7a shows the mean plasma concentration–time profiles of AC from microemulsions, 
whereas Table 3 summarizes the mean pharmacokinetic parameters after administration of the 
equivalent doses via different administration routes. Following topical application of the 
microemulsions FLAc and FMAc, the peak plasma concentrations of AC were 275.57 ± 
109.49 and 281.31 ± 76.76 ng/ml, respectively, and were reached at 0.44 ± 0.19 and 0.74 ± 
0.32 h. Due to the bicontinuous structure of the formulations and the suggested localization of 
AC (Todosijević et al., 2014), a close contact with skin might have contributed to the direct 
release of AC, without transfer of AC from inner to continuous phase and then further onto 
the skin, which may explain a short tmax in the case of SE-based microemulsions. Moreover, 
pH value of formulations indicated the presence of a large fraction of unionized drug, which 
can dissolve rapidly in the lipids of the SC, thereby facilitating transport by passive diffusion, 
and hence skin penetration of drugs (Beetge et al., 2000; Cordero et al., 1997). However, 
despite the same structure and low pH value, AC absorption from sample FPAc was delayed 
(cmax = 150.23 ± 69.74 ng/ml, tmax = 2.41 ± 2.70 h). These results, in parallel with a slower AC 
release from P80-based system (Fig. 5), further indicated that the dermal/transdermal delivery 
of AC is dependent on the surfactant structure. When comparing the in vivo pharmacokinetic 
data with skin penetration results, a similar trend is observable, confirming both, the action of 
SEs as penetration enhancers, and superiority of SE-based over P-based microemulsions. 
Diclofenac is the major metabolite of AC in rats (Noh et al., 2015). As shown in Fig. 7a and 
b, concentrations of diclofenac after topical application of AC-loaded microemulsions were 
higher than those of AC. Additionally, AUC value of diclofenac was more than threefold 
greater than AUC of AC after s.c. injection. By comparing cmax and AUC of AC and 
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diclofenac (Table 3) after topical administration of microemulsions and s.c application of AC 
solution, it can be concluded that AC metabolism was more pronounced after topical 
application, which is accordant with a higher esterase concentration in the epidermal cells and 
near to hair follicles than in the dermis of rat (Oesch et al., 2014). In addition, the rapid 
decrease in AC concentration after i.v. and s.c. administration of AC solution (Fig. 7a and b 
inset) reflected the fast disposition and elimination. Similar values for half-life (t1/2) were 
observed after i.v. and s.c. application (2.77 ± 1.53 and 4.00 ± 0.08 h, respectively). The 
values of t1/2 after topical application of microemulsions could not be precisely calculated 
from the obtained data, as AC absorption overlapped with its overall elimination. In this 
situation, drug is in the elimination phase while still being absorbed and t1/2 cannot be 
calculated correctly (El-Laithy et al., 2011). 
Absolute bioavailability of AC (Fabs) from all tested transdermal formulations was less than 
5% (Table 3), which is in accordance with low AUC or Fabs values after percutaneous 
administration of other NSAIDs as well (Brunner et al., 2005; Brunner et al., 2011; 
Heyneman et al., 2000; Kienzler et al., 2010; Rhee et al., 2013; Toshiaki et al., 1988). 
Interestingly, Fabs following s.c. application of AC was also very low. Relative bioavailability 
(Frel) of AC was therefore calculated (transdermal vs. s.c. administration), and the values of 
Frel greater than 30% (Table 3) indicated that AC successfully penetrated the SC and passed 
epidermis and dermis after application of the SE-based microemulsions. The low absolute 
bioavailability suggests that both AC and diclofenac possibly accumulated and diffused into 
deeper tissues rather than in circulation. Kienzler et al. (2010) suggested that intra-articular 
tissues may act as reservoirs for topically applied NSAIDs, emphasizing that topical 
application may allow an NSAID to achieve high intra-articular concentrations without high 
concentration of drug in the bloodstream. Before drawing further conclusions, it is necessary 
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to examine whether the concentration of AC, delivered via the formulated microemulsions, is 
locally high enough to have a therapeutic effect in the inflamed musculoskeletal tissues. 
4. Conclusion 
Microemulsions for topical AC application were successfully developed, using natural SEs 
and synthetic P as non-ionic surfactants. Indirect (conductivity, DSC) and direct (AFM) 
characterization techniques proved a bicontinuous structure of all colloidal carrier systems. 
According to the in vivo skin irritation study, the SE-based microemulsion systems containing 
IPA as a cosurfactant were well-tolerated irrespective of surfactant chain length, whereas the 
samples FP and FT were associated with a certain degree of irritation, probably related to the 
presence of P80 and Transcutol P, respectively. The comparable tendencies were observed in 
the in vitro release, in vivo tape stripping and in vivo pharmacokinetic studies: the presence of 
SEs improved the rate and extent of release and penetration/absorption of AC. Indeed, the 
dermatopharmacokinetic profiles and AUC values showed that SEs facilitated the penetration 
and bioavailability of the drug. The SE-based microemulsions appeared to be superior over 
the P80-based microemulsion, and such enhanced topical delivery needs to be further tracked 
by assessing attainable concentrations of AC in musculoskeletal tissues and effectiveness in 
animal models of inflammation. 
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Figure Captions 
 
Fig. 1. DSC cooling curves of AC-unloaded and AC-loaded microemulsions. 
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Fig. 2. (a) DSC thermograms and (b) FTIR spectra of pure AC, AC-unloaded and AC-loaded 
microemulsions. 
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Fig. 3. AFM 2D error signal, 2D and 3D topography images showing the structures of the 
samples: (a) FL, and (b) FLAc. 
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Fig. 4. In vivo safety assessment – percentage change in (a) stratum corneum hydration 
(SCH), (b) erythema index (EI), and (c) transepidermal water loss (TEWL) of the skin, after 
occlusion removal vs. baseline measurements, for investigated placebo samples, non-treated 
control without (NCWO) and under occlusion (NCO). (a) ###p < 0.001 values after occlusion 
removal compared to the basal values; ***p < 0.001 % change of SCH of placebo samples 
compared to the NCWO; +++p < 0.001 % change of SCH of placebo samples compared to the 
NCO; (b) #p < 0.05 and ##p < 0.01 values after occlusion removal compared to the basal 
values; **p < 0.01 % change of EI of placebo samples compared to the NCWO; ++p < 0.01 % 
change of EI of placebo samples compared to the NCO; (c) #p < 0.05 and ##p < 0.01 values 
after occlusion removal compared to the basal values; *p < 0.05 and **p < 0.01 % change of 
TEWL of placebo samples compared to the NCWO. Bold line and whiskers represent the 
mean value ± SD. 
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Fig. 5. The release profiles of AC from microemulsions. Data represent the mean value ± SD. 
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Fig. 6. (a) Comparative penetration profiles of AC from microemulsions assessed through 
tape stripping technique across the SC path-length L; (b) Total amount of AC penetrated from 
microemulsions. **p < 0.01 compared to FPAc. Data represent mean ± SEM. 
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Fig. 7. (a) AC plasma concentration–time profiles of microemulsions after topical application. 
Inset: AC plasma concentration–time profiles after intravenous and subcutaneous application 
of AC solution; (b) Diclofenac plasma concentration–time profiles of microemulsions after 
topical application. Inset: Diclofenac plasma concentration–time profiles after intravenous 
and subcutaneous application of AC solution. Data represent average of three to five trials ± 
SEM. 
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Tables 
Table 1. Composition of microemulsion formulations.  
Microemulsion composition (%, w/w)  FL FM FP FT 
Sucrose laurate/Isopropyl alcohol* 58.5    
Sucrose myristate/Isopropyl alcohol*  58.5   
Polysorbate 80/Isopropyl alcohol*   58.5  
Sucrose myristate/Transcutol P*    58.5 
Isopropyl myristate  6.5 6.5 6.5 6.5 
Ultra-purified water  35.0 35.0 35.0 35.0 
*Surfactant-to-cosurfactant weight ratio 1:1. 
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Table 2. Electrical conductivity, viscosity and pH values of AC-unloaded and AC-loaded 
microemulsions. Data represent the mean value ± SD. 
 AC-Unloaded Microemulsions AC-Loaded Microemulsions 
Formulations Conductivity 
[µs/cm] 
Viscosity 
[mPa s] 
pH Conductivity 
[µs/cm] 
Viscosity 
[mPa s] 
pH 
FL 58.13 ± 0.21 16.87* 6.48 ± 
0.01 
63.9 ± 0.10 18.31* 3.38 ± 
0.01 
FM 50.50 ± 0.82 19.88* 6.32 ± 
0.02 
56.83 ± 0.21 19.62* 3.22 ± 
0.01 
FP 23.10 ± 0.1 26.81* 7.59 ± 
0.01 
29.47 ± 0.15 26.42* 4.01 ± 
0.01 
*The apparent viscosity values at the shear rate of 375 s−1. 
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Table 3. Pharmacokinetic parameters from the plasma concentration-time curves. 
Application route  
 Topical Subcutaneous Intravenous 
FLAc FMAc FPAc 
cmax [ng/ml] 275.57 ± 
109.49  
281.31 ± 
76.76  
150.23 ± 
69.74 
2341.74 ± 
593.72 
69231.37 ± 
68716.47 
tmax [h] 0.44 ± 0.19 0.74 ± 0.32 2.41 ± 2.70 0.33 ± 0.00 0.00 ± 0.00 
AUC0-24 
[ngh/ml] 
1368.77 ± 
619.58  
1762.56 ± 
656.55  
1118.65 ± 
838.83 
4557.54 ± 
1360.63 
76431.63 ± 
72634.09 
Fabs [%] 1.82 2.35 1.49 6.08 / 
Frel [%] 30.62 39.43 25.03 / / 
c*max [ng/ml] 684.08 ± 
676.14 
369.12 ± 
131.91 
371.05 ± 
139.31 
2374.11 ± 
723.42 
14408.96 ± 
5613.66 
t*max [h] 2.67 ± 2.89 4.00 ± 2.45 9.75 ± 9.60 0.75 ± 0.32 0.33 ± 0.00 
AUC*0-24 
[ngh/ml] 
7051.88 ± 
3378.72 
5465.67 ± 
1755.88 
7169.57 ± 
3177.83 
14245.90 ± 
5139.21 
39633.45 ± 
26878.04 
F*abs [%] 7.39 6.35 7.28 16.52 / 
F*rel [%] 45.66 39.20 44.95 / / 
cmax, Peak plasma concentration of aceclofenac; tmax, Time of aceclofenac peak plasma 
concentration; AUC, Area under the curve of aceclofenac; Fabs, Absolute bioavailability; Frel, 
Relative bioavailability (transdermal vs. subcutaneous administration); c*max, Peak plasma 
concentration of diclofenac; t*max, Time of diclofenac peak plasma concentration; AUC*, Area 
under the curve of diclofenac; F*abs, Absolute bioavailability of total aceclofenac and 
diclofenac concentrations; F*rel, Relative bioavailability of total aceclofenac and diclofenac 
concentrations (transdermal vs. subcutaneous administration). Results are expressed as the 
mean value ± SD. 
